Michelle Alexandra Burgin

Ms. Michelle Alexandra Burgin

Arizona State University, Tempe, Arizona, USA
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 April 2020 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Jacek KwiecienJacek Kwiecien
Jacek Kwiecien
Liqiang ZhangLiqiang Zhang
Liqiang Zhang
Jordan YaronJordan Yaron
Jordan Yaron
LSLauren Schutz
Lauren Schutz
CKChristian J. Kwiecien-Delaney
Christian J. Kwiecien-Delaney
ALAlexandra Lucas
Alexandra Lucas
Spinal cord injury (SCI) results in massive secondary damage characterized by a prolonged inflammation with phagocytic macrophage invasion and tissue destruction. In prior work, sustained subdural infusion of anti-inflammatory compounds reduced neurological deficits and reduced pro-inflammatory cell invasion at the site of injury leading to improved outcomes. We hypothesized that implantation of a hydrogel loaded with an immune modulating biologic drug, Serp-1, for sustained delivery after crush-induced SCI would have an effective anti-inflammatory and neuroprotective effect. Rats with dorsal column SCI crush injury, implanted with physical chitosan-collagen hydrogels (CCH) had severe granulomatous infiltration at the site of the dorsal column injury, which accumulated excess edema at 28 days post-surgery. More pronounced neuroprotective changes were observed with high dose (100 µg/50 µL) Serp-1 CCH implanted rats, but not with low dose (10 µg/50 µL) Serp-1 CCH. Rats treated with Serp-1 CCH implants also had improved motor function up to 20 days with recovery of neurological deficits attributed to inhibition of inflammation-associated tissue damage. In contrast, prolonged low dose Serp-1 infusion with chitosan did not improve recovery. Intralesional implantation of hydrogel for sustained delivery of the Serp-1 immune modulating biologic offers a neuroprotective treatment of acute SCI.

31 March 2020 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Jordan YaronJordan Yaron
Jordan Yaron
Liqiang ZhangLiqiang Zhang
Liqiang Zhang
QGQiuyun Guo
Qiuyun Guo
MBMichelle Alexandra Burgin
Michelle Alexandra Burgin
LSLauren Schutz
Lauren Schutz
ALAlexandra Lucas
Alexandra Lucas
Viruses are widely used as a platform for the production of therapeutics. Vaccines containing live, dead and components of viruses, gene therapy vectors and oncolytic viruses are key examples of clinically-approved therapeutic uses for viruses. Despite this, the use of virus-derived proteins as natural sources for immune modulators remains in the early stages of development. Viruses have evolved complex, highly effective approaches for immune evasion. Originally developed for protection against host immune responses, viral immune-modulating proteins are extraordinarily potent, often functioning at picomolar concentrations. These complex viral intracellular parasites have “performed the R&D”, developing highly effective immune evasive strategies over millions of years. These proteins provide a new and natural source for immune-modulating therapeutics, similar in many ways to penicillin being developed from mold or streptokinase from bacteria. Virus-derived serine proteinase inhibitors (serpins), chemokine modulating proteins, complement control, inflammasome inhibition, growth factors (e.g., viral vascular endothelial growth factor) and cytokine mimics (e.g., viral interleukin 10) and/or inhibitors (e.g., tumor necrosis factor) have now been identified that target central immunological response pathways. We review here current development of virus-derived immune-modulating biologics with efficacy demonstrated in pre-clinical or clinical studies, focusing on pox and herpesviruses-derived immune-modulating therapeutics.

22 October 2020 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
Jordan YaronJordan Yaron
Jordan Yaron
Liqiang ZhangLiqiang Zhang
Liqiang Zhang
QGQiuyun Guo
Qiuyun Guo
EAEnkidia A. Awo
Enkidia A. Awo
MBMichelle Alexandra Burgin
Michelle Alexandra Burgin
ALAlexandra Lucas
Alexandra Lucas
Complex dermal wounds represent major medical and financial burdens, especially in the context of comorbidities such as diabetes, infection and advanced age. New approaches to accelerate and improve, or “fine tune” the healing process, so as to improve the quality of cutaneous wound healing and management, are the focus of intense investigation. Here, we investigate the topical application of a recombinant immune modulating protein which inhibits the interactions of chemokines with glycosaminoglycans, reducing damaging or excess inflammation responses in a splinted full-thickness excisional wound model in mice. M-T7 is a 37 kDa-secreted, virus-derived glycoprotein that has demonstrated therapeutic efficacy in numerous animal models of inflammatory immunopathology. Topical treatment with recombinant M-T7 significantly accelerated wound healing when compared to saline treatment alone. Healed wounds exhibited properties of improved tissue remodeling, as determined by collagen maturation. M-T7 treatment accelerated the rate of peri-wound angiogenesis in the healing wounds with increased levels of TNF, VEGF and CD31. The immune cell response after M-T7 treatment was associated with a retention of CCL2 levels, and increased abundances of arginase-1-expressing M2 macrophages and CD4 T cells. Thus, topical treatment with recombinant M-T7 promotes a pro-resolution environment in healing wounds, and has potential as a novel treatment approach for cutaneous tissue repair.

16 May 2022 in Pathogens
Verified
Journal Article
Open access
PDF file
IZIsabela R. Zanetti
Isabela R. Zanetti
MBMichelle Alexandra Burgin
Michelle Alexandra Burgin
Liqiang ZhangLiqiang Zhang
Liqiang Zhang
SYSteve T. Yeh
Steve T. Yeh
SASriram Ambadapadi
Sriram Ambadapadi
ALAlexandra Lucas
Alexandra Lucas
Immune cell invasion after the transplantation of solid organs is directed by chemokines binding to glycosaminoglycans (GAGs), creating gradients that guide immune cell infiltration. Renal transplant is the preferred treatment for end stage renal failure, but organ supply is limited and allografts are often injured during transport, surgery or by cytokine storm in deceased donors. While treatment for adaptive immune responses during rejection is excellent, treatment for early inflammatory damage is less effective. Viruses have developed highly active chemokine inhibitors as a means to evade host responses. The myxoma virus-derived M-T7 protein blocks chemokine: GAG binding. We have investigated M-T7 and also antisense (ASO) as pre-treatments to modify chemokine: GAG interactions to reduce donor organ damage. Immediate pre-treatment of donor kidneys with M-T7 to block chemokine: GAG binding significantly reduced the inflammation and scarring in subcapsular and subcutaneous allografts. Antisense to N-deacetylase N-sulfotransferase1 (ASONdst1) that modifies heparan sulfate, was less effective with immediate pre-treatment, but reduced scarring and C4d staining with donor pre-treatment for 7 days before transplantation. Grafts with conditional Ndst1 deficiency had reduced inflammation. Local inhibition of chemokine: GAG binding in donor organs immediately prior to transplant provides a new approach to reduce transplant damage and graft loss.

28 October 2020
Verified
Book Chapter
Closed access
PDF file
MBMichelle Alexandra Burgin
Michelle Alexandra Burgin
Jordan YaronJordan Yaron
Jordan Yaron
LZLiqiang Zhang
Liqiang Zhang
QGQiuyun Guo
Qiuyun Guo
JDJuliane Daggett
Juliane Daggett
ALAlexandra R. Lucas
Alexandra R. Lucas